Pancreas-Targeting Capsids
Metabolic Disorders
Pre-clinicalActive
Key Facts
About rAAVen Therapeutics
rAAVen Therapeutics is a Stockholm-based biotech developing a proprietary platform for engineering novel AAV capsids to overcome key limitations in gene therapy delivery, such as off-target effects and immunogenicity. The company's rAAptr platform integrates rational peptide design inspired by evolutionary biology with DNA barcoding and NGS to discover capsids with tailored tropism for diverse tissues. Operating as a platform and partnering company, rAAVen is pre-revenue and actively seeking collaborations with biotech and pharma partners to advance capsids for specific therapeutic programs. Its technology holds promise for improving the precision and efficacy of gene therapies across multiple organ systems.
View full company profileTherapeutic Areas
Other Metabolic Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel GLP-1 Receptor Agonist | lupin | Pre-clinical/Clinical |
| Undisclosed Metabolic Program | Kallyope | Discovery |
| Metabolic Disorders Program | Seragon Biosciences | Pre-clinical |
| PPARγ Program | Micar Innovation | Discovery |
| IVL-001 | InVirtuoLabs | Discovery |
| AmorphOX GLP-1 | Orexo | Preclinical |
| Amylin Program | Orion Biotechnology | Discovery |
| Not specifically disclosed on public website | Taisho Pharmaceutical | Various |
| TLC590 | Taiwan Liposome Company | Phase 2 |